It Is a Capital Mistake to Theorize Who to Treat with Checkpoint Inhibitors before One Has Data.

Abstract

Immunotherapy results in remarkable clinical benefit in a subset of cancer patients by activating the patient's own immune system. The factors determining which cancer patients will benefit are diverse. Success in realizing precision immunotherapy needs collaboration to bring together multiple diverse data sets. Defining multi-factorial biomarker algorithms for immunotherapy requires new approaches and methodologies that use deep molecular and cellular profiling of the tumor microenvironment, systemic immunity with clinical metadata from clinical trials, and other databases.

• Authors: Christine N Spencer, Daniel K Wells, Theresa M LaVallee
• Journal: Trends in cancer (Trends Cancer) Vol. 5 Issue 2 Pg. 79-82 (02 2019) ISSN: 2405-8025 [Electronic] United States
• PMID: 30755306 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2019 Elsevier Inc. All rights reserved.

Chemical References

• Biomarkers, Tumor

Topics

• Biomarkers, Tumor (immunology)
• Humans
• Immunotherapy (methods)
• Neoplasms (drug therapy)